NBRV
Closed
Nabriva Therapeutics Ag
0.4
-0.1 (-22.22%)
Last Update: 02 Oct 2023 16:30:00
Yesterday: 0.45
Day's Range: 0.4 - 0.45
Send
sign up or login to leave a comment!
When Written:
1.75
Nabriva Therapeutics AG is a biopharmaceutical company that focuses on the development and commercialization of novel antibiotics to treat serious infections caused by multi-drug resistant bacteria. The company was founded in 2006 and is headquartered in Vienna, Austria, with additional offices in Dublin, Ireland and King of Prussia, Pennsylvania.
Nabriva's lead product is lefamulin, a first-in-class semi-synthetic pleuromutilin antibiotic that targets the bacterial ribosome and is active against a wide range of Gram-positive bacteria, including those that are resistant to other antibiotics. In 2019, the U.S. Food and Drug Administration (FDA) approved lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) in adults.
In addition to lefamulin, Nabriva is also developing a pipeline of other antibiotic candidates, including CONTEPO, a potential treatment for complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), and BC-7013, a topical pleuromutilin antibiotic for the treatment of skin and soft tissue infections (SSTIs).
Nabriva has partnerships with various pharmaceutical companies, including Merck & Co. for the co-development and commercialization of lefamulin in certain territories, and Sinovant Sciences for the development and commercialization of lefamulin in China.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Nabriva's lead product is lefamulin, a first-in-class semi-synthetic pleuromutilin antibiotic that targets the bacterial ribosome and is active against a wide range of Gram-positive bacteria, including those that are resistant to other antibiotics. In 2019, the U.S. Food and Drug Administration (FDA) approved lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) in adults.
In addition to lefamulin, Nabriva is also developing a pipeline of other antibiotic candidates, including CONTEPO, a potential treatment for complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), and BC-7013, a topical pleuromutilin antibiotic for the treatment of skin and soft tissue infections (SSTIs).
Nabriva has partnerships with various pharmaceutical companies, including Merck & Co. for the co-development and commercialization of lefamulin in certain territories, and Sinovant Sciences for the development and commercialization of lefamulin in China.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!